Clinical Report: Reprogramming Macrophages via Scavenger Receptor-Mediated Nanodelivery

Overview

This review discusses scavenger receptor-guided and cathepsin B-triggered nanodelivery systems for reprogramming macrophages.

Background

Macrophages are crucial components of the innate immune system, exhibiting significant plasticity in response to various stimuli. Their roles in cancer and atherosclerosis are concerning, as they can contribute to immune suppression and disease progression.

Data Highlights

No numerical data or trial data was provided in the source material.

Key Findings

• Macrophages can adopt diverse functional states influenced by microenvironmental signals.
• Scavenger receptors are targets for selective delivery of therapeutic agents to diseased macrophages.
• Cathepsin B serves as a trigger for the release of therapeutic payloads from nanocarriers.
• Macrophage reprogramming is a goal in addressing therapeutic resistance in cancer and atherosclerosis.
• Challenges in translational applications include off-target effects and heterogeneity in macrophage populations.

Clinical Implications

The integration of nanomedicine with macrophage biology offers a novel approach to modulate immune responses in disease.

Conclusion

Advancements in nanomedicine present new avenues for reprogramming macrophages.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Macrophage-mediated nutrient recycling: evolutionary insights into the metabolic role of professional phagocytes
2. The ASCO Post, 2015 -- Adding CD47 to Artificial Antigen-Presenting Cells May Stimulate T-Cell Responses and Improve Functionality
3. Frontiers in Immunology, 2026 -- Immunomodulatory effects of synthetic antimicrobial peptides on LPS-induced inflammatory responses in THP-1 macrophages
4. Frontiers in Immunology, 2026 -- Nanomedicine delivery systems remodel the immunosuppressive microenvironment of colorectal cancer: synergistic strategies and mechanisms of targeted immune checkpoint inhibitors
5. Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies - PMC
6. 2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy? | European Heart Journal - Cardiovascular Pharmacotherapy | Oxford Academic
7. Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies - PMC
8. 2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy? | European Heart Journal - Cardiovascular Pharmacotherapy | Oxford Academic
9. Study Details | NCT06551805 | Clinical Research Protocol of Ferumoxytol for Magnetic Resonance Enhancement Imaging in Patients With Atherosclerosis. | ClinicalTrials.gov
10. Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I) - PubMed
11. Phase 2 Trial of VGT-309: Cathepsin-Based Near-Infrared Probe for Intraoperative Molecular Imaging - PMC
12. Cathepsin B-Activated Prodrug for Precision Tumor Theranostics | Journal of Medicinal Chemistry
13. Precision engineering of macrophage reprogramming with RNA interference-loaded lipid nanoparticles: a game-changer in cancer immunotherapy | Drug Delivery and Translational Research | Springer Nature Link